<DOC>
	<DOCNO>NCT01599884</DOCNO>
	<brief_summary>N-acetylcysteine ( NAC ) describe mucolytic antioxidant property . It widely prescribe patient chronic obstructive pulmonary disease ( COPD ) , particularly accompany symptom chronic cough sputum production . Randomized , placebo control indicate safe may clinical benefit use relatively low dos . It postulate substantially high dos NAC well-tolerated provide well symptom control also decrease blood maker oxidant stress inflammation .</brief_summary>
	<brief_title>N-Acetylcysteine Patients With COPD ChronicBronchitis</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Inclusion Criteria Capability provide write informed consent Age ≥ 40 year ≤ 85 year FEV1/FVC ratio ( post bronchodilator ) &lt; 70 % FEV1 ( post bronchodilator ) &lt; 65 % Presence chronic cough sputum production define follow : Presence chronic cough sputum define response first two question SGRQ ( see Appendix A ) . Subjects respond positively question 1 ( cough ) question 2 ( sputum ) SGRQ either `` several day per week '' `` almost every day '' eligible Current former smoker lifetime cigarette consumption least 10 packyears Negative serum pregnancy test baseline visit patient premenopausal female ( menopause define absence menstrual cycle last 12 month ) Must fluent speak English language Exclusion Criteria Not fully recover least 30 day COPD exacerbation characterize typical symptom treat antibiotic prednisone Known allergy sensitivity NAC albuterol Any patient unstable cardiac disease Any patient document history uncompensated congestive heart failure last 2 year Clinical diagnosis asthma , bronchiectasis , cystic fibrosis , severe alpha1 antitrypsin deficiency Active lung cancer history lung cancer le 2 year since lung resection treatment . If history lung cancer , must evidence recurrence 2 year precede baseline visit . Undergoing active treatment malignancy except hormonal therapy ( i.e . prostate cancer , breast cancer ) nonmetastatic skin cancer symptomatic Chronic kidney disease estimate GFR &lt; 30 ml/min . GFR estimate use Modification Diet Renal Disease ( MDRD ) formula History cirrhosis evidence portal hypertension ( ascites , chronic edema ) Participation pulmonary rehabilitation program completion within past 6 week Prisoners institutionalized patient Participation another study involve investigational product within 30 day baseline visit Pregnant breastfeeding patient . Use guaifenesin last 30 day Currently long act nitrate angina heart failure Abnormalities screen blood work define : WBC &lt; 3.0 &gt; 15.0 K/cmm Hemoglobin &lt; 9.0 &gt; 17.0 gm/dl Platelets &lt; 75 &gt; 400 K/cmm ALT &gt; 3 time upper limit normal INR &gt; 1.5 unless warfarin therapy Any concomitant condition might endanger patient participation study interfere study procedure , assess investigator</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>Chronic bronchitis</keyword>
	<keyword>N-acetylcysteine</keyword>
</DOC>